CA2315746A1 - Vaccin a base de lipooligosaccharide destine a la prevention d'infections dues a moraxella (branhamella) catarrhalis chez les mammaliens - Google Patents

Vaccin a base de lipooligosaccharide destine a la prevention d'infections dues a moraxella (branhamella) catarrhalis chez les mammaliens Download PDF

Info

Publication number
CA2315746A1
CA2315746A1 CA002315746A CA2315746A CA2315746A1 CA 2315746 A1 CA2315746 A1 CA 2315746A1 CA 002315746 A CA002315746 A CA 002315746A CA 2315746 A CA2315746 A CA 2315746A CA 2315746 A1 CA2315746 A1 CA 2315746A1
Authority
CA
Canada
Prior art keywords
dlos
los
catarrhalis
isolated
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002315746A
Other languages
English (en)
Inventor
Xin-Xing Gu
John B. Robbins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Government
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2315746A1 publication Critical patent/CA2315746A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

L'invention concerne un vaccin conjugué contre Moraxella (Branhamella) catarrhalis comprenant un lipooligosaccharide isolé dont on retiré des acides gras estérifiés pour produire un lipooligosaccharide détoxiqué (dLOS), ou dont on a retiré un lipide A pour produire un oligosaccharide détoxiqué (OS), qui est lié à un excipient immunogène. Le vaccin s'utilise pour la prévention de l'otite moyenne et des infections respiratoires provoquées par M. catarrhalis chez des mammaliens, y compris des humains.
CA002315746A 1998-01-13 1999-01-12 Vaccin a base de lipooligosaccharide destine a la prevention d'infections dues a moraxella (branhamella) catarrhalis chez les mammaliens Abandoned CA2315746A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7148398P 1998-01-13 1998-01-13
US60/071,483 1998-01-13
PCT/US1999/000590 WO1999036086A1 (fr) 1998-01-13 1999-01-12 Vaccin a base de lipooligosaccharide destine a la prevention d'infections dues a moraxella (branhamella) catarrhalis chez les mammaliens

Publications (1)

Publication Number Publication Date
CA2315746A1 true CA2315746A1 (fr) 1999-07-22

Family

ID=22101617

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002315746A Abandoned CA2315746A1 (fr) 1998-01-13 1999-01-12 Vaccin a base de lipooligosaccharide destine a la prevention d'infections dues a moraxella (branhamella) catarrhalis chez les mammaliens

Country Status (9)

Country Link
EP (1) EP1047447A1 (fr)
JP (1) JP2002509115A (fr)
KR (1) KR20010034124A (fr)
CN (1) CN1288384A (fr)
AU (2) AU2221299A (fr)
BR (1) BR9906902A (fr)
CA (1) CA2315746A1 (fr)
IL (1) IL136903A0 (fr)
WO (1) WO1999036086A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089839A1 (fr) * 2001-05-03 2002-11-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunisation intranasale par un lipooligosaccharide detoxifie provenant d'un haemophilus influenzae ou d'un moraxella catarrhalis non typable
US20040126381A1 (en) 1996-04-23 2004-07-01 Xin-Xing Gu Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella
US6391313B1 (en) * 1999-07-15 2002-05-21 Aventis Pasteur Limited Multi-component vaccine to protect against disease caused by Haemophilus influenzae and Moraxella catarrhalis
WO2006085910A2 (fr) * 2004-06-04 2006-08-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Moraxella catarrhalis exempte d'endotoxine
CN104592365B (zh) * 2013-11-01 2019-06-14 中国人民解放军军事医学科学院毒物药物研究所 梭曼抗原、梭曼疫苗及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7701098A (en) * 1997-05-28 1998-12-30 Michael A. Apicella Laft mutants of pathogenic gram-negative bacteria

Also Published As

Publication number Publication date
KR20010034124A (ko) 2001-04-25
AU2003200964A1 (en) 2003-06-12
BR9906902A (pt) 2000-10-17
CN1288384A (zh) 2001-03-21
EP1047447A1 (fr) 2000-11-02
JP2002509115A (ja) 2002-03-26
AU2003200964B2 (en) 2004-11-11
WO1999036086A1 (fr) 1999-07-22
AU2221299A (en) 1999-08-02
AU2003200964A8 (en) 2003-06-12
IL136903A0 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
US6531131B1 (en) Conjugate vaccine for Neisseria meningitidis
US9533032B2 (en) Protein matrix vaccines and related methods of making and administering such vaccines
JP2763960B2 (ja) 大腸菌 ｏ−多糖−タンパク質結合ワクチン
US6207157B1 (en) Conjugate vaccine for nontypeable Haemophilus influenzae
EP2026841B1 (fr) Procédé de conjugaison de la poly-n-acetyl glucosamine(pnag) et une proteine porteuse
US6685949B1 (en) Lipooligosaccharide based vaccine for prevention of moraxella (branhamella)catarrhalis infections in humans
US20010048929A1 (en) Novel multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US20120231086A1 (en) Protein matrix vaccines of improved immunogenicity
AU2003200964B2 (en) Lipooligosaccharide-Based Vaccine for Prevention of Moraxella (Branhamella) Catarrhalis Infections in Mammals
JPH07503238A (ja) コレラ予防用の無毒化ｌｐｓ−コレラ毒素結合ワクチン
Zou et al. Preparation of glycoconjugate vaccines
EP0471954A2 (fr) Conjugué immunogénique d'oligosaccharides non toxiques dérivés du lipooligosaccharide de Bordetella pertussis
JP5967585B2 (ja) ワクチンとして使用される無毒化大腸菌易熱性エンテロトキシン（ｌｔ）との多糖結合
US20030068324A1 (en) Conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid
MXPA00006678A (en) Lipooligosaccharide-based vaccine for prevention of moraxella
Robbins et al. Synthesis and Characterization of
MXPA00008255A (en) Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued